Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $22,800.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 4,000 shares of the business’s stock in a transaction on Monday, July 13th. The stock was sold at an average price of $5.70, for a total transaction of $22,800.00. Following the transaction, the insider directly owned 610,887 shares in the company, valued at $3,482,055.90. This trade represents a 0.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

• On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.17, for a total value of $38,221.81.
• On Monday, April 20th, Zhenyu Xu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.21, for a total value of $3,167.68.

SOPHiA GENETICS Stock Performance

SOPH traded down $0.04 during trading on Tuesday, reaching $5.68. 120,863 shares of the company’s stock were exchanged, compared to its average volume of 190,422. The company has a market capitalization of $476.50 million, a P/E ratio of -10.92 and a beta of 0.96. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05. The business has a 50 day moving average price of $5.18 and a 200 day moving average price of $4.99. SOPHiA GENETICS SA has a fifty-two week low of $2.92 and a fifty-two week high of $6.30.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The business had revenue of $21.69 million for the quarter, compared to the consensus estimate of $20.40 million.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on SOPH shares. BTIG Research reaffirmed a “buy” rating and set a $8.00 price objective on shares of SOPHiA GENETICS in a report on Monday, June 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, SOPHiA GENETICS has an average rating of “Hold” and an average target price of $7.50.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SOPH. 1492 Capital Management LLC bought a new stake in SOPHiA GENETICS during the fourth quarter worth about $973,000. Royce & Associates LP acquired a new stake in shares of SOPHiA GENETICS during the fourth quarter worth approximately $2,009,000. Hodges Capital Management Inc. bought a new position in shares of SOPHiA GENETICS in the first quarter valued at approximately $2,157,000. Royal Bank of Canada boosted its holdings in shares of SOPHiA GENETICS by 3,130.2% in the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after acquiring an additional 18,781 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. acquired a new position in shares of SOPHiA GENETICS in the 2nd quarter worth approximately $567,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.